Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 18:10:2042098619869077.
doi: 10.1177/2042098619869077. eCollection 2019.

Risk of bronchospasm and coronary arteriospasm with sugammadex use: a post marketing analysis

Pushkar Aggarwal  1
Affiliations

Risk of bronchospasm and coronary arteriospasm with sugammadex use: a post marketing analysis

Pushkar Aggarwal. Ther Adv Drug Saf. .

Abstract

Introduction: Sugammadex is used for the reversal of neuromuscular blockade caused by rocuronium bromide and vecuronium bromide. As part of the post licensing phase of drug development, adverse events related to the use of sugammadex are still being uncovered and being reported. The potential association between sugammadex and adverse events bronchospasm and coronary arteriospasm using a retrospective pharmacovigilance signal analysis was carried out.

Methods: Food and Drug Administration's Adverse Event Reporting System database was used to run disproportionality analyses to investigate the potential association of sugammadex with bronchospasm or coronary arteriospasm. In this analysis we report the adverse event signal using frequentist methods of Relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR) and the Bayesian based Information Component metric.

Results: A statistically significant disproportionality signal is found between sugammadex and bronchospasm (n = 44; chi-squared = 2993.87; PRR = 71.95 [95% CI: 54.00-95.85]) and sugammadex and coronary arteriospasm (n = 6; chi-squared = 209.39; PRR = 43.82 [95% CI: 19.73-97.33]) as per Evans criteria. Both statistically significant disproportionality signals persisted when stratified by gender. Based upon dynamic cumulative PRR graph, the PRR value has steadily increased and the 95% CI narrowed since December 2012.

Conclusion: The results of the pharmacovigilance analysis highlight a statistically significant disproportionality signal between sugammadex usage and bronchospasm and coronary arteriospasm adverse events. Physicians need to be aware of these adverse events when using sugammadex. The results of the pharmacovigilance signal analysis highlight a statistically significant disproportionality signal between sugammadex usage and bronchospasm and coronary arteriospasm adverse events. Physicians need to be aware of these adverse events when using sugammadex.

Keywords: Bronchospasm; Coronary Arteriospasm; Sugammadex.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author declares that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Dynamic cumulative proportional reporting ratio (PRR) of sugammadex and bronchospasm events since December 2012.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Renew J, Naguib M, Brull S. Clinical use of neuromuscular blocking agents in anesthesia. UpToDate, https://www.uptodate.com/contents/clinical-use-of-neuromuscular-blocking... (2017, accessed 5 August 2018).
    1. Bevan DR. Neuromuscular blocking drugs: onset and intubation. J ClinAnesth 1997; 9(Suppl. 6): 36S–39S. - PubMed
    1. Pani N, Dongare PA, Mishra RK. Reversal agents in anaesthesia and critical care. Indian J Anaesth 2015; 59: 664–669. - PMC - PubMed
    1. World Health Organization. WHO model list of essential medicines, http://www.who.int/medicines/publications/essentialmedicines/18th_EML.pdf (accessed 5 August 2018).
    1. Food and Drug Administration. Bridion application summary review, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000S... (accessed 5 August 2018).